A Phase 2 study of the dual MET/VEGFR2 inhibitor XL880 in patients (pts) with papillary renal carcinoma (PRC)

被引：0
|
作者：
Ross, Robert W. [1 ]
Srinivasan, Ramaprasad [2 ]
Vaishampayan, Ulka [3 ]
Bukowski, Ronald [4 ]
Rosenberg, Jonathan [5 ]
Eisenberg, Peter [6 ]
Logan, Theodore [7 ]
Srinivas, Sandhya [8 ]
Stein, Mark [9 ]
Mueller, Thomas [10 ]
Keer, Harold N. [10 ]
机构：
[1] Dana Farber Canc Inst, Boston, MA USA
[2] Natl Canc Inst, Urol Oncol Branch, Bethesda, MD USA
[3] Karmanos Canc Ctr, Detroit, MI USA
[4] Cleveland Clin, Cleveland, OH USA
[5] Univ Calif San Francisco, San Francisco, CA USA
[6] California Canc Ctr, Greenbrae, CA USA
[7] Indiana Univ, Ctr Canc, Indianapolis, IN USA
[8] Stanford Univ, Ctr Canc, Stanford, CA 94305 USA
[9] Inst Canc Res, New Brunswick, NJ USA
[10] Exelixis Inc, San Francisco, CA USA
来源：
MOLECULAR CANCER THERAPEUTICS | 2007年 / 6卷 / 12期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：3511S / 3511S
页数：1
相关论文
共 50 条
  • [41] Potent antitumor activity of XL184 (cabozantinib), a c-MET and VEGFR2 inhibitor, in colorectal cancer patient-derived tumor explant models.
    Atreya, Chloe E.
    Song, Eun-Kee
    Messersmith, Wells
    Purkey, Alicia
    Bagby, Stacey
    Quackenbush, Kevin
    Kelley, Robin K.
    Kwak, Eunice
    Ryan, David
    Venook, Alan
    Arcaroli, John J.
    CANCER RESEARCH, 2013, 73 (08)
  • [42] Lenvatinib and pembrolizumab in patients with metastatic papillary renal cell carcinoma: A phase 2 pilot study.
    Tsimafeyeu, Ilya
    Sultanbaev Sr, Alexander
    Vilkov, Sergey
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (23_SUPPL) : 109 - 109
  • [43] Safety and efficacy of MET inhibitor tivantinib (ARQ 197) combined with sorafenib in patients (pts) with renal cell carcinoma (RCC) from a phase I study.
    Puzanov, Igor
    Sosman, Jeffrey Alan
    Santoro, Armando
    Martell, Robert E.
    Dy, Grace K.
    Goff, Laura Williams
    Ma, Wen Wee
    Fetterly, Gerald J.
    Michael, Shaunita A.
    Means-Powell, Julie Ann
    Chai, Feng
    Lamar, Maria
    Strauss, Gary M.
    Zucali, Paolo A.
    Chiang, Wendy M.
    Jarboe, Jamie
    Schwartz, Brian E.
    Adjei, Alex A.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [44] Phase 1/2 study of sunitinib in combination with gefitinib in patients (pts) with metastatic renal cell carcinoma (mRCC)
    Redman, B. G.
    Hudes, G. R.
    Kondagunta, G. V.
    Patel, P. H.
    Kim, S. T.
    Chen, I.
    Motzer, R. J.
    EJC SUPPLEMENTS, 2007, 5 (04): : 302 - 302
  • [45] Phase 2 Study of Bevacizumab and Temsirolimus After VEGFR TKI in Metastatic Renal Cell Carcinoma
    Mahoney, Kathleen M.
    Jacobus, Susanna
    Bhatt, Rupal S.
    Song, Jiaxi
    Carvo, Ingrid
    Cheng, Su-Chun
    Simpson, Mekailah
    Fay, Andre P.
    Puzanov, Igor
    Michaelson, M. Dror
    Atkins, Michael B.
    McDermott, David F.
    Signoretti, Sabina
    Choueiri, Toni K.
    CLINICAL GENITOURINARY CANCER, 2016, 14 (04) : 304 - +
  • [46] An Oral Small Molecule VEGFR2 Inhibitor, Apatinib, in Patients with Recurrent or Refractory Cervical Cancer: A Real World Study
    Li, Ning
    Wang, Ziyi
    Yuan, Guangwen
    Sun, Yangchun
    Zhang, Rong
    Li, Xiaoguang
    Li, Nan
    Wang, Jing
    Wu, Lingying
    JOURNAL OF ONCOLOGY, 2020, 2020
  • [47] Updated results from a phase 2 study of the oral vascular endothelial growth factor receptor 2 (VEGFR2) inhibitor rivoceranib for recurrent or metastatic (R/M) adenoid cystic carcinoma (ACC).
    Kang, Hyunseok
    Ahn, Myung-Ju
    Keam, Bhumsuk
    Bowles, Daniel W.
    Wong, Deborah J. L.
    Ho, Alan Loh
    Kim, Sung-Bae
    Worden, Francis P.
    Jang, Tak Yun Seong
    Meng, Xianzhang
    Hanna, Glenn J.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [48] A PHASE I/II STUDY OF FORETINIB, AN ORAL MULTIKINASE INHIBITOR TARGETING MET, RON, AXL, TIE-2 AND VEGFR IN ADVANCED HEPATOCELLULAR CARCINOMA (HCC)
    Yau, T.
    Yen, C. -J.
    Chen, P. -J.
    Chau, Y.
    Lencioni, R.
    Kallender, H.
    Ottesen, L. H.
    Poon, R. T. -P.
    JOURNAL OF HEPATOLOGY, 2011, 54 : S268 - S268
  • [49] A phase I/II study of foretinib, an oral multikinase inhibitor targeting MET, RON, AXL, TIE-2, and VEGFR in advanced hepatocellular carcinoma (HCC).
    Yau, Thomas Cheung
    Sukeepaisarnjaroen, Wattana
    Chao, Yee
    Yen, Chia-Jui
    Lausoontornsiri, Wirote
    Chen, Pei-Jer
    Sanpajit, Theeranun
    Lencioni, Riccardo
    Camp, Aaron C.
    Cox, Donna S.
    Kallender, Howard
    Ottesen, Lone Harild
    Poon, Ronnie Tung-Ping
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [50] Pharmacodynamically guided dose selection of PF-00337210, a VEGFR2 tyrosine kinase (TK) inhibitor, in a phase I study.
    Liu, G.
    LoRusso, P.
    Heath, E. I.
    Bruce, J. Y.
    Traynor, A. M.
    Pilat, M.
    Breazna, A.
    Tortorici, M.
    Shalinsky, D. R.
    Ricart, A. D.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
12345